期刊文献+

三氧化二砷联合紫杉醇对A549细胞增殖和裸鼠异位肿瘤生长的影响 被引量:3

Effect of As_2O_3 and paclitaxel on the proliferation of A549 cell and ectopic tumor growth of nude mice
下载PDF
导出
摘要 目的探讨三氧化二砷(As_2O_3)联合紫杉醇(paclitaxel,PTX)对肺癌的治疗作用。方法噻唑蓝法(methyl thiazdyl tetrazolium,MTT)检测As_2O_3联合PTX抑制肺癌A549细胞的增殖。采用激光共聚焦显微镜观察给药后对肺癌A549细胞的凋亡诱导作用。通过构建体外肿瘤球模型观察给药后对肿瘤球的生长抑制,模拟给药后药物在体内对肿瘤生长的抑制能力。建立肺癌裸鼠移植瘤模型,随机分为生理盐水组、As_2O_3干预组、PTX干预组和联合干预组。每天分别用设定浓度的生理盐水、As_2O_3、PTX、As_2O_3+PTX对移植瘤小鼠腹腔内注射给药。观察给药后肿瘤大小的变化,计算抑瘤率。对肿瘤切片分别采用苏木精-伊红染色法(hematoxylin-eosin staining,HE)进行染色,考察As_2O_3、PTX、As_2O_3+PTX诱导体内肿瘤细胞凋亡的效果。结果肺癌A549细胞给药48 h后,生理盐水组、As_2O_3干预组、PTX干预组和联合干预组对肿瘤细胞的抑制率分别为(3.35±0.21)%、(47.55±2.25)%、(64.64±3.35)%和(84.58±3.76)%,各药物干预组与生理盐水组相比,差异的具有统计学意义(P<0.01)。生理盐水组诱导肿瘤细胞早期凋亡率为0.26%,As_2O_3干预组为9.7%,PTX干预组为17.8%,联合干预组为42.5%,而与生理盐水组、As_2O_3干预组和PTX干预组相比,联合干预组能够增加肿瘤细胞早期凋亡率,差异具有统计学意义(P<0.01)。肿瘤球给药7d后生理盐水组肿瘤球体积增大1.36倍,As_2O_3干预组、PTX干预组和联合干预组分别使肿瘤体积减小到原体积的(77.35±2.31)%、(61.68±2.44)%和(44.85±3.34)%,差异均具有统计学意义(P<0.01)。荷瘤裸鼠治疗实验以生理盐水组为对照,As_2O_3干预组、PTX干预组和联合干预组对肿瘤生长的抑制率分别为(22.4±4.5)%、(39.5±6.2)%和(69.5±7.3)%,联合干预组与其他组间差异具有统计学意义(P<0.01)。结论As_2O_3能够有效增强PTX抑制A549细胞的增殖和裸鼠异位肿瘤的生长,As_2O_3联合PTX可能作为肺癌潜在有效的治疗手段。 Objective To evaluate the effect of As2O3 combined with paclitaxel(PTX)on the treatment of lung cancer.Methods The anti-proliferation efficiency of As2 O3 combined with PTX was evaluated by MTT assay.Tumor spheroids were used to evaluate anti-tumor ability of As2 O3 combined with PTX.Transmission electron microscope (TEM)were used to observe the apoptosis morphous.A549 cell were xenografted in mice to establish the animal model,and the nude mices were devided into four groups,saline group,As2 O3 group,PTX group and As2 O3 +PTX group.The animal model were used to evaluate the effect of anti-tumor.The tumor size of every group were measured.HE was used to observe the apoptosis of cancer cells. Results The cell inhibition rate of A549 cell were(3.35 ±0.21)%,(47.55 ±2.25)%,(64.64 ±3.35)%and(84.58 ±3.76)%after treatment with saline,As2O3,PTX and As2O3combined with PTX after 48h respectively(P<0.01).The early apoptosis rate of cancer cells were 0.26%,9.7%, 17.8% and 42.5% for saline group,As2 O3 group,PTX and As2 O3 +PTX group respectively(P<0.01 ).The final tumor spheroid volumes in saline group increased 1.36 times after 7 days.The final tumor spheroid volumes reduced to(77.35 ±2.31)%,(61.68 ±2.44)% and(44.85 ±3.34)% in As2O3,PTX and As2O3 combined with PTX group respectively(P<0.01).The inhibition of lung cancer in vitro demonstrated the inhibition rate of tumor growth compared with saline group were(22.4 ±4.5)%,(39.5 ±6.2)% and(69.5 ±7.3)% for As2O3,PTX and As2O3 +PTX,respectively(P<0.01 ).Conclusion As2 O3 combined with PTX can effectively inhibit the proliferation of A549 cells and ectopic tumor growth in nude mice and it may be a potentially effective treatment for lung cancer.
出处 《中国生化药物杂志》 CAS 北大核心 2014年第4期66-69,共4页 Chinese Journal of Biochemical Pharmaceutics
关键词 As2 O3 紫杉醇 肺肿瘤 联合药物疗法 动物模型 As2O3 paclitaxel lung neoplasm combination drug therapy animal models
  • 相关文献

参考文献11

  • 1Jingwei Li,Liang Feng,Li Fan,Yuan Zha,Liangran Guo,Qizhi Zhang,Jun Chen,Zhiqing Pang,Yuchen Wang,Xinguo Jiang,Victor C. Yang,Longping Wen.Targeting the brain with PEG–PLGA nanoparticles modified with phage-displayed peptides[J].Biomaterials.2011(21)
  • 2Yutao Liu,Kai Li,Jie Pan,Bin Liu,Si-Shen Feng.Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel[J].Biomaterials.2009(2)
  • 3徐尔迪,肖延风.三氧化二砷对人胃癌裸鼠移植瘤Flt-1、KDR和VEGFR-3表达的影响[J].陕西医学杂志,2013,42(8):943-946. 被引量:8
  • 4Changyou Zhan,Bing Gu,Cao Xie,Jin Li,Yu Liu,Weiyue Lu.Cyclic RGD conjugated poly(ethylene glycol)- co -poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect[J].Journal of Controlled Release.2009(1)
  • 5Neha Shah,Kiran Chaudhari,Prudhviraju Dantuluri,R. S. R. Murthy,Susobhan Das.Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic&lt;sup&gt;?&lt;/sup&gt;P85, an in vitro cell line and in vivo biodistribution studies on rat model[J].Journal of Drug Targeting.2009(7)
  • 6李海燕,曹励民,王娟.三氧化二砷对人肝癌SMMC-7721细胞增殖、迁移及侵袭能力的影响[J].中国老年学杂志,2013,33(11):2572-2574. 被引量:15
  • 7王绩英,王涛,曾锦荣,刘春妮,莫碧文,陈梅唏,陈峰,林武洲.三氧化二砷联合非诺贝特对人肺癌A549细胞上皮间质转化及E-cadherin/Snail转化因子的影响[J].第三军医大学学报,2012,34(14):1406-1410. 被引量:9
  • 8Shunichi Sugawara,Makoto Maemondo,Motoko Tachihara,Akira Inoue,Osamu Ishimoto,Tomohiro Sakakibara,Kazuhiro Usui,Hiroshi Watanabe,Nobumichi Matsubara,Kana Watanabe,Kenya Kanazawa,Takashi Ishida,Yasuo Saijo,Toshihiro Nukiwa.Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601[J].Lung Cancer.2013(1)
  • 9Alejandro Soriano-Hernández,Hector Galvan-Salazar,Daniel Montes-Galindo,Alejandrina Rodriguez-Hernandez,Rafael Martinez-Martinez,Jose Guzman-Esquivel,Laura Valdez-Velazquez,Luz Baltazar-Rodriguez,Francisco Espinoza-Gómez,Augusto Rojas-Martinez,Rocio Ortiz-Lopez,Rafael Gonzalez-Alvarez,Ivan Delgado-Enciso.Antitumor effect of meclofenamic acid on human androgen-independent prostate cancer: a preclinical evaluation[J].International Urology and Nephrology.2012(2)
  • 10刘洪义,王权,于金海,王大广,所剑.紫杉醇联合三氧化二砷作用人结肠腺癌LS-174T细胞增殖及凋亡的实验研究[J].中国实验诊断学,2009,13(3):324-327. 被引量:9

二级参考文献48

共引文献35

同被引文献22

  • 1Jemal A, Bray F, Center MM, et al. International variations in bladder cancer incidence and mortality [J]. Eur Urol,2014,66( 1 ) :59-73.
  • 2Henry NL, Macvicar G, Hussain M. Management of patients with mus- cle-invasive and metastatic bladder cancer [J]. Oneology, 2005,19 (10) :1333-1342.
  • 3黄金杯,薛学义,郑清水,等.丝裂霉素c与羟基喜树碱对膀胱癌术后化疗的有效性及安全性比较的Meta分析[J].中国生化药物杂志,2008,6(34):6434-6438.
  • 4Chert G,He Y,Wu X,et al. In vitro and in vivo studies of pirarubicin- loaded SWNT for the treatment of bladder cancer[ J]. Braz J Med Biol Res ,2012,45 (8) :771-776.
  • 5Zhang X,Jia S,Yang S,et al. Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells by increasing the tumor suppressor PTEN expression[J]. J Cell Biochem,2012,113 (11 ):3528-3535.
  • 6Rosenfeld MR, Ye X, Supko JG,et a/. A phase I./II trial of hydrexy- chlorequine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed g[iohlastoma multiformc ~J~ . Autophagy, 2014, 10 (8):1359-1368.
  • 7Vogl DT, Stadtmauer EA, Tan KS, et al. Combined autophagy and proteasemc inhibition : A phase 1 trial of hydroxychloroquine and bort- ezomth in patients with relapsed/refractory myeloma ~ J ~ . Autoph- agy, 2014, 10(8) :1380-1390.
  • 8Rangwala R, Leone R, Chang YC, a a/. Phase I trial of hydroxy- chloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma [J] . Autophagy, 2014, 10(8) :1369- 1379.
  • 9Mahalingam D, Mita M, Sarantopoulos J, et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinet- ic, and pharmacedynamic analysis of hydroxychloroquine in combina- tion with the HDAC inhibitor vorinostat in patients with advanced sol- id tumors [J] . Autophagy, 2014, 10(8) :1403-1414.
  • 10Rangwala R, Chang YC, Hu J, et 02. Combined MTOR and autoph- agy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma [ J ] . Autophagy, 2014, 10 (8):1391-1402.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部